{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T08:06:17Z","timestamp":1768896377678,"version":"3.49.0"},"reference-count":32,"publisher":"Spandidos Publications","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Ther Med"],"DOI":"10.3892\/etm.2023.12000","type":"journal-article","created":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T12:12:02Z","timestamp":1683634322000},"source":"Crossref","is-referenced-by-count":2,"title":["High\u2011dose aflibercept injection has striking effects on myopic choroidal neovascularization"],"prefix":"10.3892","volume":"25","author":[{"given":"Wei","family":"Zhu","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250013, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanlei","family":"Hao","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250013, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongfang","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250013, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunmei","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250013, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2023,5,9]]},"reference":[{"key":"key20230526101756_b1-ETM-25-6-12000","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.preteyeres.2012.04.001","article-title":"Choroidal neovascularization in pathological myopia","volume":"31","author":"Neelam","year":"2012","journal-title":"Prog Retin Eye Res"},{"key":"key20230526101756_b2-ETM-25-6-12000","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ajo.2013.08.010","article-title":"Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: An evidence-based systematic review","volume":"157","author":"Wong","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"key20230526101756_b3-ETM-25-6-12000","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1136\/bjo.87.5.570","article-title":"Patchy atrophy and lacquer cracks predispose to the development of choroidal neovascularization in pathological myopia","volume":"87","author":"Ohno-Matsui","year":"2003","journal-title":"Br J Ophthalmol"},{"key":"key20230526101756_b4-ETM-25-6-12000","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1136\/bjo.2009.163535","article-title":"Choroidal filling delay in choroidal neovascularization due to pathological myopia","volume":"94","author":"Wakabayashi","year":"2010","journal-title":"Br J Ophthalmol"},{"key":"key20230526101756_b5-ETM-25-6-12000","doi-asserted-by":"publisher","first-page":"3721","DOI":"10.1167\/iovs.09-3493","article-title":"Ocular risk factors for choroidal neovascularization in pathologic myopia","volume":"51","author":"Ikuno","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key20230526101756_b6-ETM-25-6-12000","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/00006982-199212020-00009","article-title":"Pathologic findings in pathologic myopia","volume":"12","author":"Grossniklaus","year":"1992","journal-title":"Retina"},{"key":"key20230526101756_b7-ETM-25-6-12000","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.2174\/1389450122999210128180725","article-title":"Anti-VEGF therapy in myopic CNV","volume":"22","author":"Toto","year":"2021","journal-title":"Curr Drug Targets"},{"key":"key20230526101756_b8-ETM-25-6-12000","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s10792-010-9346-3","article-title":"Photodynamic therapy for choroidal neovascularization in young adult patients","volume":"30","author":"Ehrlich","year":"2010","journal-title":"Int Ophthalmol"},{"key":"key20230526101756_b9-ETM-25-6-12000","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1001\/archopht.118.3.327","article-title":"A preliminary study of photodynamic therapy using verteporfin for choroidal neovascularization in pathologic myopia, ocular histoplasmosis syndrome, angioid streaks and idiopathic causes","volume":"118","author":"Sickenberg","year":"2000","journal-title":"Arch Ophthalmol"},{"key":"key20230526101756_b10-ETM-25-6-12000","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1097\/IAE.0b013e3181b1bb1a","article-title":"Anti-VEGF drugs as the 2009 first-line therapy for choroidal neovascularization in pathologic myopia","volume":"29","author":"Cohen","year":"2009","journal-title":"Retina"},{"key":"key20230526101756_b11-ETM-25-6-12000","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1007\/s40265-016-0605-0","article-title":"Management of myopic choroidal neovascularization: Focus on anti-VEGF therapy","volume":"76","author":"Teo","year":"2016","journal-title":"Drugs"},{"key":"key20230526101756_b12-ETM-25-6-12000","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1097\/01.iae.0000242842.14624.e7","article-title":"Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration","volume":"26","author":"Ferrara","year":"2006","journal-title":"Retina"},{"key":"key20230526101756_b13-ETM-25-6-12000","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1097\/01.iae.0000240121.28034.c3","article-title":"Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab","volume":"26","author":"Laud","year":"2006","journal-title":"Retina"},{"key":"key20230526101756_b14-ETM-25-6-12000","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1177\/1120672119883590","article-title":"Comparison of structural and functional outcome of aflibercept versus ranibizumab in patients with myopic choroidal neovascularization","volume":"31","author":"Howaidy","year":"2021","journal-title":"Eur J Ophthalmol"},{"issue":"e57642","key":"key20230526101756_b15-ETM-25-6-12000","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0057642","article-title":"Structural characterization of a recombinant fusion protein by instrumental analysis and molecular modeling","volume":"8","author":"Wu","year":"2013","journal-title":"PLoS One"},{"key":"key20230526101756_b16-ETM-25-6-12000","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.ophtha.2015.01.025","article-title":"Intravitreal aflibercept injection in patients with myopic choroidal neovascularization: The MYRROR study","volume":"122","author":"Ikuno","year":"2015","journal-title":"Ophthalmology"},{"key":"key20230526101756_b17-ETM-25-6-12000","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1007\/s10792-022-02261-1","article-title":"The efficacy of different anti-vascular endothelial growth factor agents and prognostic biomarkers in monitoring of the treatment for myopic choroidal neovascularization","volume":"42","author":"Karasu","year":"2022","journal-title":"Int Ophthalmol"},{"key":"key20230526101756_b18-ETM-25-6-12000","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1007\/s00417-021-05547-9","article-title":"Comparison of agents using higher dose anti-VEGF therapy for treatment-resistant neovascular age-related macular degeneration","volume":"260","author":"Broadhead","year":"2022","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"key20230526101756_b19-ETM-25-6-12000","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1097\/IAE.0000000000001726","article-title":"High-dose high-frequency aflibercept for recalcitrant neovascular age-related macular degeneration","volume":"38","author":"You","year":"2018","journal-title":"Retina"},{"key":"key20230526101756_b20-ETM-25-6-12000","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1089\/jop.2011.0261","article-title":"Evaluation of very high-and very low-dose intravitreal aflibercept in patients with neovascular age-related macular degeneration","volume":"28","author":"Nguyen","year":"2012","journal-title":"J Ocul Pharmacol Ther"},{"key":"key20230526101756_b21-ETM-25-6-12000","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1007\/s00417-016-3396-9","article-title":"Intravitreal aflibercept for myopic choroidal neovascularization","volume":"254","author":"Pece","year":"2016","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"key20230526101756_b22-ETM-25-6-12000","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/eye.2015.199","article-title":"Aflibercept as primary treatment for myopic choroidal neovascularisation: A retrospective study","volume":"30","author":"Bru\u00e8","year":"2016","journal-title":"Eye (Lond)"},{"key":"key20230526101756_b23-ETM-25-6-12000","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.2147\/OPTH.S117791","article-title":"Intravitreal aflibercept for the treatment of choroidal neovascularization associated with pathologic myopia: A pilot study","volume":"10","author":"Korol","year":"2016","journal-title":"Clin Ophthalmol"},{"key":"key20230526101756_b24-ETM-25-6-12000","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1136\/bjophthalmol-2015-308264","article-title":"Clinical correlation to differences in ranibizumab and aflibercept vascular endothelial growth factor suppression times","volume":"100","author":"Fauser","year":"2016","journal-title":"Br J Ophthalmol"},{"issue":"342","key":"key20230526101756_b25-ETM-25-6-12000","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-021-02088-x","article-title":"Result of intravitreal aflibercept injection for myopic choroidal neovascularization","volume":"21","author":"Chen","year":"2021","journal-title":"BMC Ophthalmol"},{"key":"key20230526101756_b26-ETM-25-6-12000","doi-asserted-by":"publisher","first-page":"e615","DOI":"10.1111\/aos.12457","article-title":"One-year outcome of two different initial dosing regimens of intravitreal ranibizumab for myopic choroidal neovascularization","volume":"92","author":"Kung","year":"2014","journal-title":"Acta Ophthalmol"},{"key":"key20230526101756_b27-ETM-25-6-12000","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1089\/jop.2019.0080","article-title":"Comparison of efficacy of intravitreal ranibizumab and aflibercept in eyes with myopic choroidal neovascularization: 24-month follow-up","volume":"36","author":"Korol","year":"2020","journal-title":"J Ocul Pharmacol Ther"},{"key":"key20230526101756_b28-ETM-25-6-12000","author":"Zhu"},{"issue":"14389","key":"key20230526101756_b29-ETM-25-6-12000","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-32761-z","article-title":"Intravitreal aflibercept versus bevacizumab for treatment of myopic choroidal neovascularization","volume":"8","author":"Wang","year":"2018","journal-title":"Sci Rep"},{"key":"key20230526101756_b30-ETM-25-6-12000","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1177\/1120672120963455","article-title":"Three-year real-world outcomes of intravitreal anti-VEGF therapies in patients affected by myopic choroidal neovascularization","volume":"31","author":"Corazza","year":"2021","journal-title":"Eur J Ophthalmol"},{"key":"key20230526101756_b31-ETM-25-6-12000","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1136\/bjo.2006.099598","article-title":"The international intravitreal bevacizumab safety survey: Using the internet to assess drug safety worldwide","volume":"90","author":"Fung","year":"2006","journal-title":"Br J Ophthalmol"},{"key":"key20230526101756_b32-ETM-25-6-12000","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ophtha.2015.09.002","article-title":"Intravitreal bevacizumab versus ranibizumab for treatment of neovascular age-related macular degeneration: Findings from a cochrane systematic review","volume":"123","author":"Solomon","year":"2016","journal-title":"Ophthalmology"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"deposited":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T10:21:31Z","timestamp":1685096491000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/etm.2023.12000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,9]]},"references-count":32,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,5,9]]}},"URL":"https:\/\/doi.org\/10.3892\/etm.2023.12000","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,9]]},"article-number":"301"}}